Synthetic lethality represents an emerging therapeutic paradigm in neurodegenerative disease that exploits vulnerabilities created by specific genetic backgrounds or pathological states. This approach has transformed oncology and holds promise for targeting the unique metabolic and cellular defects present in tauopathies like corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP)[1].
Synthetic lethality occurs when the combination of two genetic alterations produces cell death, while either alteration alone is tolerable. In the context of neurodegeneration:
In CBS/PSP, several pathological states create potential synthetic lethal vulnerabilities:
Poly(ADP-ribose) polymerase 1 (PARP1) is a nuclear enzyme that plays dual roles in neurodegeneration:
Protective function: DNA damage detection and repair through base excision repair (BER)
Pathological function: Overactivation leads to:
Tau pathology directly drives PARP1 activation through multiple mechanisms[2:1]:
PARP inhibitors provide neuroprotection through multiple pathways[3]:
| Pathway | Mechanism | Therapeutic Implication |
|---|---|---|
| NAD+ preservation | Prevent excessive consumption | Maintain energy metabolism |
| Sirtuin activation | Enable PGC-1α deacetylation | Mitochondrial biogenesis |
| Neuroinflammation reduction | Inhibit NF-κB pathway | Reduce microglial activation |
| DNA repair modulation | Maintain BER without exhaustion | Prevent cell death |
| Drug | Company | CNS Penetration | Status | Notes |
|---|---|---|---|---|
| Olaparib | AstraZeneca | Moderate | Phase 1 (CNS) | FDA-approved for ovarian/breast cancer |
| Veliparib | AbbVie | Good | Phase 1 (CNS) | Being evaluated for combination therapy |
| Niraparib | GSK | Moderate | Preclinical | Investigated for neuroprotection |
| Rucaparib | Clovis | Moderate | Preclinical | Being studied for brain bioavailability |
Overactivation of PARP1 leads to catastrophic NAD+ depletion through excessive poly(ADP-ribosyl)ation[9]:
SIRT1 (Silent Information Regulator 2 homolog 1) is an NAD+-dependent deacetylase with neuroprotective properties in tauopathy[11]:
Combining PARP inhibitors with SIRT1 activators creates multiple benefits:
| Compound | Mechanism | Evidence Level | Notes |
|---|---|---|---|
| Resveratrol | Direct SIRT1 activation | Phase 2 | Limited brain penetration |
| SRT2104 | Synthetic SIRT1 agonist | Phase 1 | Better bioavailability |
| SRT1720 | SIRT1-selective activator | Preclinical | Being optimized for CNS |
| Pterostilbene | SIRT1 activation | Clinical | Natural analog, better PK |
Given this 50-year-old male with suspected CBS/PSP (alpha-synuclein negative):
| Medication | Interaction | Risk Level | Management |
|---|---|---|---|
| Levodopa | None known | Low | Standard dosing |
| Rasagiline | MAO-B + PARPi: theoretical serotonin syndrome | Moderate | Monitor for serotonergic signs, avoid high-dose PARPi |
| Criterion | Score | Rationale |
|---|---|---|
| Novelty | 8/10 | New mechanism for tauopathy |
| Evidence | 5/10 | Strong preclinical, minimal clinical |
| Translation | 6/10 | Available compounds, off-label use |
| Safety | 6/10 | Known safety profile from oncology |
| Synergy | 7/10 | Combines with existing approaches |
| Total | 32/50 | Modest overall |
Cao L, et al. "Synthetic lethality in neurodegenerative diseases: opportunities for therapeutic targeting". Nat Rev Neurol. 2023. ↩︎
Zhou J, et al. "PARP1 promotes tau pathology". Nat Neurosci. 2020. ↩︎ ↩︎ ↩︎
Iyiran S, et al. "PARP inhibitors in neurodegenerative disease: beyond DNA repair". Pharmacol Ther. 2021. ↩︎
Kim TW, et al. "PARP-1 in dopaminergic neuron death". Mol Neurobiol. 2018. ↩︎
Mandir AS, et al. "PARP inhibition protects against MPTP-induced parkinsonism". Proc Natl Acad Sci USA. 1999. ↩︎
Liu H, et al. "PARP and alpha-synuclein aggregation". Mol Neurodegener. 2021. ↩︎
Wu PJ, et al. "PARP improves DNA repair and cognition in AD models". Cell Rep. 2022. ↩︎
Song L, et al. "PARP inhibition extends survival in ALS models". Brain. 2022. ↩︎
Minhas PS, et al. "NAD+ repletion improves mitochondrial and stem cell function". Nature. 2021. ↩︎
Xie Y, et al. "NAD+ precursor and PARP inhibitor combination". Nat Commun. 2021. ↩︎
Tenisson S, et al. "SIRT1 activators and neuroprotection in tauopathy". J Neurochem. 2022. ↩︎